News 

2022 Award Ibex.JPG

April 1, 2022

Ibex receives a Top Biotechnology Start-up award for 2022 from Life Sciences Review Magazine. Click Here to view Article.

February 11, 2021

Ibex announces publication of PCBP1 use for generating Stem Cells while inhibiting oncogenesis patent pending

The disclosure provides compositions and methods of using gene therapy to create induced pluripotent stem cells (iPSCs) without inducing cancer or tumorigenesis. The methods disclosed herein employ plasmids and vectors that contain transcription factors and an anti-oncogene such as PCBP1 which inhibits the expression of cancer biomarkers and concomitant oncogenesis.  WO2021026488A2 - Use of pcbp1 to generate induced pluripotent stem cells while inhibiting oncogenesis - Google Patents

December 31, 2020

Ibex announces completion of Phase 1 SBIR Grant

Ibex Biosciences has successfully delivered upon the aims of its anti-MIF SBIR Phase 1 Grant Award.

October 9, 2019

Ibex announces publication of FILAMIN-A patent pending

The disclosure teaches antibodies that are useful, inter alia, in methods for detecting and treating human cancer. In a particular aspect, the disclosure teaches novel antibodies that are useful for detecting and treating human breast cancer. In some embodiments, the disclosure teaches novel antibodies that bind to filamin A. In some embodiments, the antibodies are intrabodies.  https://patents.google.com/patent/WO2020076954A1

August 8, 2019

Ibex announces publication of PCBP1 patent pending

The present disclosure provides compositions and methods of using gene therapy to decrease cell migration and metastasis and reduce tumor mass or burden. The methods disclosed herein employ plasmids, vectors, and non-viral vectors that contain PCBP1 and/or PCBP1 mutants which inhibit the expression of cancer biomarkers and decrease cell migration or tumor size.   https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019153008

September 20, 2017

Ibex announces SBIR award

Ibex Biosciences will continue to develop anti-MIF VHH antibodies by establishing larger production levels of the VHH and testing them in animal models. Our work will start with construction and expression of anti-MIF VHH and VHH-Fc antibodies. Successful feasibility work will focus on their characterization and demonstration of their functional antibody binding in cell lines and animal models. While MIF has been demonstrated to play significant roles in many oncologic conditions, this evaluation will focus on prostate cancer for an initial proof of concept. Subsequent development efforts will expand to other solid tumor cancers as well as inflammatory diseases. http://grantome.com/grant/NIH/R43-CA224732-01